The Study of Safety and Preliminary Efficacy of Aleeto in Patients With MultIple System Atrophy
A legfontosabb adatok
- Ki végzi
- Beijing Tiantan Hospital
- Hol
- Beijing (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- Korai 1. fázis
- Résztvevők
- 20 fő, tervezett
- Kezdés
- 2025. máj. 31.
- Várható befejezés
- 2026. dec. 31.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport nem kap vizsgálati kezelést, összehasonlításként.
- A vizsgált kezelések
- Aleeto
- A regiszteradat frissítve
- 2025. szeptember 3.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with multiple system atrophy of the parkinsonian type (MSA-P). It tests the safety and early effects of Aleeto.
- Életkor
- 30 to 75 years
- Nem
- All sexes can join.
- A betegség stádiuma
- Clinically confirmed or clinically probable MSA-P. Movement symptoms started 5 years or less before the first visit. Able to walk 10 meters or more alone or with a walking aid. Expected to live at least 1 year.
- Korábbi kezelés
- Levodopa has helped poorly. No vaccination within 1 month. No other experimental drugs within 1 month or 5 drug half-lives.
A részvétel fő kizáró okai
- Dementia, or memory test scores showing dementia
- Brain MRI showing another brain disease, bleeding, tumor or other major problem
- Cancer, epilepsy, or blood clotting problems
- Active hepatitis B, hepatitis C, or HIV
- Pregnant, breast-feeding, or planning pregnancy
A regiszter feltételei, szó szerint
Mind a 22 feltétel megnézéseKevesebb
Ki vehet részt
- 1.30 years ≤ 75 years of age, regardless of sex; 2.Clinically confirmed or clinically probable MSA-P; 3.Poor response to levodopa; 4.MSA-related motor symptom onset ≤5 years at first visit; 5.Walking ≥10 meters independently or with a walking aid; 6.Expected survival of ≥1 year, as determined by the investigator; 7.Signed informed consent
Ki nem vehet részt
- Patients with MMSE scores indicative of dementia prior to enrolment (≤17 points for illiterate individuals, ≤20 points for individuals with elementary school education, ≤24 points for individuals with junior high school education or higher) or those with a prior confirmed diagnosis of dementia
- Presence of immune disorders that are inadequately controlled or require treatment with biological agents
- Patients who have received any vaccination within 1 month
- Patients with pre-existing, clearly diagnosed malignant tumor or being treated with anti-tumor drugs
- Patients who are participating in other interventional studies or using other investigational biological agents, drugs, or devices, and patients who have used other experimental drugs within 1 month or within 5 drug half-lives
- Head MRI at screening showing evidence of other CNS lesions consistent with a diagnosis of neurodegenerative disease other than MSA
- Head MRI at screening showing other significant pathological findings including but not limited to: cerebral hemorrhage, acute phase of cerebral infarction, aneurysm, vascular malformation, infectious lesion, brain tumor or other space-occupying lesion (meningiomas or arachnoid cysts with a maximum diameter of <1 cm need not be excluded)
- Known history of allergy to biological agents such as proteins and cell products
- Patients with a history of clearly diagnosed epilepsy or taking antiepileptic drugs
- Presence of lumbar spine disease and deformity or other contraindications to lumbar puncture
- Hepatitis C virus antibody positive or history of positive test
- Positive HIV test or history of positive test
- Patients with a combined history of alcohol or drug abuse or alcohol or drug dependence within 2 years
- Other psychiatric disorders diagnosed according to DSM-V diagnostic criteria, or significant suicide intent
- Patients with abnormal coagulation function prior to enrolment (e.g., platelet count <100 × 10E9/L; prothrombin time [PT] >3 s), previous diagnosis of coagulation disorders such as hemophilia, and patients currently receiving more than two types of antiplatelet medication
- With severe hepatic insufficiency, renal insufficiency or severe cardiac insufficiency (severe hepatic insufficiency refers to ALT value≥2.0 times the upper limit of normal value or AST value≥2.0 times the upper limit of normal value; severe renal insufficiency refers to CRE≥1.5 times the upper limit of normal value or eGFR<40mL/min/1.73m2; severe cardiac insufficiency refers to NYHA class 3-4)
- Hepatitis B active infection (hepatitis B surface antigen positive and/or serum HBV DNA positive or serum HBV DNA > 2 × 10E8 IU/ml
- Contraindications to MRI (e.g. claustrophobia, internal placement of pacemakers or paramagnetic metals, etc.)
- Patients who are pregnant, breast-feeding, or who are likely to become pregnant and plan to become pregnant
- Unable to be cooperative and complete the follow-up due to other reasons
- Patients who, in the opinion of the investigator, are not suitable for participation in this trial
Nézd meg, megfelelhetsz-e
Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.
- 30 és 75 év között vagy?
Helyszínek itt: Kína
- Beijing Tiantan Hospital,Capital Medical UniversityBeijing, KínaContact: Yilong Wang, M.D.Résztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This is a single-center, prospective, randomized, open-label, blinded outcome assessment (PROBE) study. At the end of the PROBE study, patients who have completed the study may opt to enter the open-label extension (OLE) study. The objective of the study is to evaluate the safety, tolerability and potential preliminary efficacy of Aleeto in the treatment of patients with multiple system atrophy (MSA).
A vizsgálat 2 csoportja
- Intervention groupA vizsgált kezelés
Intrathecal administration combined with intravenous administration of Aleeto of Aleeto was given to each MSA patient in the intervention group, with intrathecal administration on days 1, 31 and 61 and intravenous administration on days 2 to 14, 32 to 44±3 and 62 to 74±5, and treatment was given once a day. intrathecal administration: 8 mL sodium chloride injection + Aleeto (130 μg/branch) for intrathecal administration, which was completed in about 5 minutes; intravenous administration: Aleeto (130 μg/branch) was dissolved in 100 ml sodium chloride injection, which was completed in about 30-40 minutes. After completion of the above treatments and 90±7 days of follow-up, all subjects entered the OLE study phase. During this period, all participants were given the option of continuing to receive 3 phases (on Days 91 to 104±7, Days 121 to 134±7, and Days 151 to 164±7) of intravenous Aleeto administration (14 consecutive days of Aleeto 130 μg qd i.v. in each phase).
Kezelés: Aleeto
- Control groupNincs vizsgálati kezelés, összehasonlításként
Each MSA patient in the blank control group received only basic treatment with no trial-related treatment. After completion of the above treatments and 90±7 days of follow-up, all subjects entered the OLE study phase. During this period, all participants were given the option of continuing to receive 3 phases (on Days 91 to 104±7, Days 121 to 134±7, and Days 151 to 164±7) of intravenous Aleeto administration (14 consecutive days of Aleeto 130 μg qd i.v. in each phase).
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- Illeszkedési kérdések
- Forrás: NCT06765733: ki vehet részt
- A regiszteradat frissítve
- 2025. szeptember 3.